H2o Therapeutics Launches FDA-approved "Foggy" Feature for Parkinson's Disease Management on Apple Watch

h2o therapeutics has officially released Foggy, a haptic cueing feature for Apple Watch aimed at assisting individuals with Parkinson's disease, specifically addressing the symptom known as freezing of gait. Classified as a Class II Medical Device by the U.S. FDA, Foggy is available through prescription and is integrated into the Parky app. This innovative tool leverages Apple Watch's Taptic Engine to provide users with vibrotactile stimulation, aiming to improve mobility and quality of life.

Yagmur Selin Gulmus, the founder of h2o therapeutics, emphasized the importance of accessibility, individualization, and ease of use in cueing strategies for freezing of gait. The development of Foggy was informed by clinical studies and collaboration with the Parkinson's community, prioritizing user-friendly design and real-world applicability. Foggy not only offers non-invasive support by a simple tap on the Apple Watch but also serves as a data platform for better understanding and individualizing treatment for freezing of gait.

Foggy's launch coincides with World Parkinson's Day, marking a significant milestone in addressing the challenges of Parkinson's disease. Integrated into the FDA-cleared Parky app, Foggy enhances the app's capabilities in monitoring and managing symptoms like tremors and dyskinesia through real-time data exchange between patients and medical professionals. This addition seeks to provide comprehensive support for those living with Parkinson's disease, leveraging technology for improved disease management.